Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?Zacks Investment Research • 10/07/26
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research • 09/22/26
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial ResultsAccesswire • 09/22/26
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026Accesswire • 09/16/26
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026Accesswire • 06/01/26
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026Accesswire • 05/18/26
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 05/13/26
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial ResultsAccesswire • 05/13/26
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026Accesswire • 05/06/26
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 02/04/26
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial ResultsAccesswire • 02/03/26
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026Accesswire • 01/27/26
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026Accesswire • 01/13/26
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York CityAccesswire • 01/12/26
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in AdultsAccesswire • 12/15/25
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceAccesswire • 11/24/25